CDKN1A and adenocarcinoma: A good antitumor effect was also demonstrated in a murine adenocarcinoma tumor model in a study using GET of the p21 promoter-driven IL-12 plasmid in combination with local tumor irradiation, which was comparable to the same treatment using a constitutive promoter [15].